Parallax Health Sciences Inc. announced that the company is preparing a 510(K) application to be filed with the U.S. Food and Drug Administration (FDA). Currently, the FDA regulates only small subsets of mHealth apps, and drug administration. The rapid growth of mobile health (mHealth) apps has resulted in confusion amongst health care providers and the public about which products rely on evidence-based medicine. obtaining a 510(K) clearance with the FDA is a strong step forward toward differentiating Fotodigm® technology, while developing trust in the marketplace that it has been reviewed and cleared by the FDA. Alongside the development of a trusted technology, is the ability for Fotodigm® to obtain Current Procedural Terminology (“CPT”) codes. The CPT codes will allow for a substantial broadening of the medical community for billing for services”. Mr. Arena continued, “With the newly authorized CPT Codes that went into effect in January 2019, the medical community and regulatory agencies have begun the incorporation of digital technologies into mainstream use. This impacts the access to care for patients and dramatically impacts the potential revenue capacity of new medical technologies, especially those targeting the management of Chronic Disease. One of the huge problems of chronic disease management, a $800 billion sector in 2017, has been the ability to generate revenue through medical reimbursement. This is an area of focus for Parallax Care since the company can reach a larger audience and achieve mission of reducing costs, expanding access, and improving outcomes of healthcare.